The gene therapy explorer
With one project nearing the clinical-study phase and one project in an early preclinical phase, CombiGene is the leading Nordic gene therapy company. Gene therapy has seen rapid development in recent years, with a number of approved therapies and several major corporate deals. During this period CombiGene built up a unique position with respect to knowledge within this field in the Nordic region. The company’s expertise covers all central areas of the gene therapy field: viral vectors, preclinical studies including biodistribution and toxicity studies, development of GMP-classed manufacturing methods, upscaling of production volumes and regulatory strategy.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene – the leading Nordic gene therapy company
CombiGene is currently conducting two gene therapeutic development projects: one for treatment of epilepsy that cannot otherwise be treated with drugs and one for treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body.
CombiGene now has a well-established international network within both the pharmaceutical industry and academia. The ambition is to form strategic partnerships for continued development and commercialization of the two projects which CombiGene is currently pursuing and to identify potential new projects in areas in which it may be possible to apply gene therapy.
CG01 – THE EPILEPSY PROJECT
Preparations are now being made in the epilepsy project for safety studies.
CombiGene´s lead project CG01 has received funding from the European Union´s Horizon 2020 research and innovationprogramme
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.